10-Q: Standard BioTools Reports Q1 2025 Results: Revenue Declines Amid Integration Efforts

Standard BioTools' Q1 2025 revenue decreased by 10% year-over-year, reflecting ongoing integration efforts and shifts in sales mix.

Summary

• Standard BioTools Inc. reported a net loss of $26.03 million for the three months ended March 31, 2025, compared to a net loss of $32.16 million for the same period in 2024.
• Total revenue decreased by 10% to $40.8 million, driven by declines in consumables and lab services revenue, partially offset by an increase in instrument revenue.
• The company's gross profit decreased by 18% to $19.7 million, with a gross margin of 48.4% compared to 53.1% in the prior year.
• Operating expenses decreased by 38% to $52.7 million, primarily due to lower research and development, selling, general, and administrative, and transaction and integration expenses.
• The company's cash and cash equivalents totaled $150.88 million as of March 31, 2025, with short-term investments of $107.18 million.
• The company reassessed its operating and reportable segments, concluding that it has one operating and reportable segment: the consolidated company.
• The company expects its existing liquidity and sources of capital will be sufficient to support its operations for at least the next 12 months.

Sentiment

Score: 6

Explanation: The report presents a mixed picture. While the net loss has improved and operating expenses have decreased, revenue is down and gross margins have declined. The company is taking steps to improve efficiency and invest in R&D, but the near-term outlook is uncertain.

Positives

• Net loss improved year-over-year, decreasing from $32.16 million to $26.03 million.
• Operating expenses decreased by 38%, indicating successful cost management efforts.
• Research and development expenses decreased by $4.7 million, or 29%, due to a reduction in employee headcount and reduced investment in certain long-term instrument projects.
• Transaction and integration expenses decreased by $16.0 million, or 93%, as merger-related activities concluded.
• The company has fully repaid its outstanding term loan facility, as well as the balance on convertible notes issued during 2019.
• The company expects its existing liquidity and sources of capital will be sufficient to support its operations for at least the next 12 months.

Negatives

• Total revenue decreased by 10% year-over-year, driven by declines in consumables and lab services revenue.
• Gross profit decreased by 18%, and gross margin declined from 53.1% to 48.4%.
• Lab services revenue declined by $2.8 million, or 19%, primarily due to elevated backlogs at the beginning of the first quarter of 2024, which contributed to higher lab services revenue in the prior-year period.
• Interest income decreased by $3.3 million, or 53%, due to lower account balances in money market funds and short-term investments.

Risks

• Continued adoption of services and products is crucial for future performance.
• The company's ability to lower operating costs is essential for improving profitability.
• Expansion of proteomic content and maintaining a competitive advantage in the proteomics market are necessary for long-term growth.
• The company has experienced operating losses since inception and has an accumulated deficit of $1,211.7 million as of March 31, 2025.
• The company's ability to fund future operations and meet debt covenant requirements will depend upon its level of future revenue and operating cash flow and its ability to access additional funding through either equity offerings, issuances of debt instruments or both.
• A decline in the company's stock price may require additional impairment analyses for its reporting unit and could be required to recognize a non-cash goodwill impairment charge in the near future.

Future Outlook

The company expects its existing liquidity and sources of capital will be sufficient to support its operations for at least the next 12 months. The company plans to continue investing in R&D and improving operating discipline to drive future growth and profitability.

Management Comments

• At Standard BioTools, Inc., we are committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world-class management team.
• Our established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster.
• We offer a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research.
• With advanced technologies in proteomics and genomics, we empower scientists to gain deeper biological insights, accelerate discoveries, and drive improved health outcomes across diverse therapeutic areas including immunology, oncology, neuroscience, cardiometabolic diseases and more.
• We have built a solid foundation supporting a differentiated portfolio of life science tools, offering broad multi-omic capabilities that drive innovation and accelerate the pace of drug development.

Industry Context

The life science tools industry is characterized by rapid innovation and consolidation. Standard BioTools' focus on multi-omics solutions and strategic acquisitions positions it to compete in this dynamic market. The company's emphasis on proteomics and genomics aligns with growing demand for advanced technologies in drug discovery and development.

Comparison to Industry Standards

• Comparing Standard BioTools to companies like Illumina, Agilent, and Thermo Fisher Scientific, it's clear that Standard BioTools is focusing on a niche market within the broader life science tools sector.
• Illumina's revenue in Q1 2025 was significantly higher, but Standard BioTools is focusing on specialized proteomics and genomics solutions.
• Agilent and Thermo Fisher Scientific have a more diversified portfolio, while Standard BioTools is concentrating on integrating its SomaScan, CyTOF, and Hyperion platforms.
• The company's gross margin of 48.4% is lower than some of its larger competitors, indicating potential for improvement through cost optimization.
• The company's focus on strategic consolidation and operational efficiency is similar to industry trends, but its success will depend on effective integration and execution.

Legal Proceedings

• The company is involved in various legal proceedings and claims arising in the ordinary course of business.
• A stockholder complaint was filed in the Delaware Court of Chancery against SomaLogic and certain officers and directors alleging Breach of Fiduciary Duty and Aiding and Abetting Breach of Fiduciary Duty.
• The company has resolved fee disputes with all but two stockholders counsel.
• Additional lawsuits against the company and certain of its officers or directors may be filed in the future.

Related Party Transactions

• In connection with the Merger, Eli Casdin, a member of the company's board of directors and the company's principal stockholder, and the former principal stockholder of SomaLogic, was issued shares of common stock, RSUs, and options.
• Casdin Partners Master Fund, L.P. and Casdin Private Growth Equity Fund, L.P. received shares of common stock in exchange for their shares of SomaLogic common stock, which shares may be deemed to be indirectly beneficially owned by Mr. Casdin.
• Warrants held by CMLS Holdings II LLC (CMLS LLC) converted into the right to receive shares of the company's common stock and CMLS LLC also received shares of common stock in exchange for its SomaLogic common stock, all of which may be deemed to be indirectly beneficially owned by Mr. Casdin.
• On March 18, 2024, Casdin and its affiliates entered into the Exchange Agreement with the Company whereby all of the outstanding shares of the Series B-1 Preferred Stock held by Casdin and its affiliates were converted into an aggregate of 46,465,458 shares of the Company's common stock.

Stakeholder Impact

• Shareholders: The decrease in revenue and gross margin may negatively impact shareholder value.
• Employees: Restructuring activities and headcount reductions may affect employee morale and job security.
• Customers: Continued investment in R&D and product development is expected to benefit customers through improved solutions.
• Suppliers: The company's purchase commitments with IDT and LGC Genomics ensure ongoing business relationships with these suppliers.

Next Steps

• Continue to focus on growth in instrument placements, including the SomaScan Authorized Sites program.
• Enhance the proteomics offering through continuous improvements to instruments and the commercial release of the LabThread SLX.
• Improve operating discipline through implementation of lean SBS principles.
• Reduce manufacturing costs by modifying assays and laboratory processes.
• Expand the proteomic content and database to drive value and market opportunities.

Key Dates

Keywords

Standard BioTools, financial results, proteomics, genomics, revenue, net loss, SomaLogic, merger, operating expenses, cash flow